Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N01AH03

Dzuveo(sufentanil citrate)

Pain

Marketing Authorisation Holder: Laboratoire Aguettant

EMA Authorisation: 25/06/2018

INN: sufentanil

Indication

Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dzuveo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.